PRISM Mid-Day Movers: Rare Disease Breakthrough and Ethereum Treasury Surge Drive Index Gains

2025-07-07 14:30:42 ET

Mustang Bio Rockets 218% After FDA Grants Orphan Drug Designation for CAR-T Therapy
Mustang Bio Inc. ( MBIO ) soared 217.73%, dominating the PRISM Emerging Biotech Index , following the FDA's Orphan Drug Designation for MB-101 , its IL13Ra2-targeted CAR T-cell therapy. The designation, which covers treatment of both astrocytomas and glioblastoma, offers regulatory incentives such as tax credits and seven years of market exclusivity. Early data from a Phase 1 trial showed promising responses, including two long-lasting complete remissions. Mustang plans to advance MB-101 in combination with its oncolytic virus MB-108, a dual approach designed to reshape the tumor microenvironment and enhance CAR-T efficacy. The recognition marks a milestone in the company's strategy to address high-grade brain tumors.

Bit Digital Climbs 29% on Ethereum-Only Treasury Strategy
Bit Digital Inc. ( BTBT ) gained 29.08%, lifting the PRISM Emerging Crypto Mining Index , after disclosing that it has shifted its entire digital asset treasury to Ethereum . With over 100,000 ETH now on the books, the company becomes one of the largest publicly traded holders of Ethereum globally. CEO Sam Tabar highlighted Ethereum's smart contract capabilities and staking model as reasons for the pivot, stating that Bit Digital aims to become a leading ETH treasury platform through institutional-grade staking and DeFi exposure.

Other PRISM Mid-Day Movers:
? Core Scientific, Inc. ( CORZ ) down 16.53%
? Knightscope, Inc. ( KSCP ) up 18.27%
? ABVC BioPharma, Inc. ( ABVC ) up 22.99%

The post PRISM Mid-Day Movers: Rare Disease Breakthrough and Ethereum Treasury Surge Drive Index Gains appeared first on PRISM MarketView .

COMTEX_467065894/2927/2025-07-07T13:30:42